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In specific Iherapy Clinically
. the effecl of immunolherapy is moslly observed by the improvement in symptoms and signs. The decrease in reactivity in skin and bronchial provocation tests and the effect of suppression are observed in some immllno--serologic tesls. On lhe other hand. with the use 0/ non-antigenic materials and modified allergen eXlraclS helpil/g IgE suppression in the extrinsic alOpic bronchial asthma is believed 10 be an effective. thrusting. low-costing and fast-recovering treatmem mel hod in the years ahead.
Introductio n Bronchial asthma is a syndrome which has a relative high incidence in the population (2070 ohotal population) and which can occur by variety orstimuli. Despite the fact that the exact etiology of the syndrome is unknown, the immuno-allergic ractors are most ly incri minated. Inherited or aquired imbalance in adrenergic, chol inergic and probably purinergic (nonadrenergic and non-cholinergic) controls of airway diameter, has also been implicated (9) . in asthmatic individuals with hyperrcactive bronchi; bronchocontriction may persist at subclinical levels (even when they are asymptomatic) (21) . Allergic dis-eases arc mostly due to the high degree of sensitivity developed against normally harmless substances. This hypersensitivity, probably developed by inherited predisposition, is commonly called as "atopy" (23) . In atopic individuals hay fever, urticaria and allergic conjunctivitis are observed together with bronchial asthma.
The mechanism of allergic reactions:
Early type or hypersensitivity reactions were first detected in early 1900's (4,6) on skin of various bronchial asthmatic patients. Atopic individuals are capable of producing large amounts of reaginic antibodies which being homocytotTophic by nature, are fixed to the mast cells or basophils. This sk in sensitizing antibody JgE, produced by submucosal plasma cells and lymph nodes in rcspi ratory and gastrointcstinal systems (30) was isolated within past 20 years (12) .
On re-exposure to the same allergen, the antigenantibody reaction results in liberation of chemical medialOrs which in turn trigger allergic reactions. Chemical mediators such as histamine. leucotriens, ECF-A etc. also cause vasodilatation. increased capillary permeability and bronchial smooth muscle contraction in bronchial asthma (13).
The atopic character in bronchial asthma is well determined by skin test positivity and increased IgE antibody (25) . Allergic skin tests are cust.omarily per· formed to detect environmemal allergens, (depending on patient's history) playing etiologic roles (28) . The allergic character of a patient in bronchial asthma is determined by the history, the relation of the syptoms to the environment, to seasonal and situational variations and his/ her clinical course (26) .
Diagnostic skin test procedure:
In our center, commercially available allergens are applied during skin tests. T he prick test method, being usually safer due to the small amoum of antigen. is preferred (24) . The skin is punctured 3·5 cm. apart on the nexor aspects of the fo rearm by a darning necdleor by a lancet. Some clinicians also use the back or ab· dominal sites for puncture (3 1). A drop of glycerineprepara ted test extract solutions is placed on each scratches and comrols are performed simultaneously (the diluent-saline·as negative comrol and 0. 1 mg/ml. histamine chloride as positive control). In the intradermal test, a tuberculin syringe with short-bevel no. 26 (hypodermic) needle is used to inject 0.01-0.02 ml. of a lyophilized test extract of allergen solutions into the skin (32) . International classifications are used 10 imerpret all skin test results (20) . On the other hand , in some cases negative results a rise from the use o f original crude extracts. In order to obtain satis factory resulls. it is necessary to develop more purified, standardized and well-characterized allergenic extract (3).
The (Qneept of immunotherapy:
The complete avoidance (elimination) of allergens being mostly difficult in the therapy of extri nsic atopic bronchial asthma. The procedure of hyposensitization was introduced for the treatment of pollenosis (hay fever) in 1911 (19) . In this form of therapy (conventional systemjc hyposensitization) the gradually increasing subcutaneous aqueus allergen extract solutions are used to increase the tolerance of the patiem agai nst offending allergens.
Depending on the patient' s reaction, injections continue at 1-7 days intervals up to the maximal tolerated dosage (MTD) or until a presel maximal dosage (usually 1.000.-10.000 times greater than initial dosage). The allergen ext racts are injected eithcr solely or by multiple regular intervals; perennial, pre-seasonal or coseasonal in pollen allergies (18) .
The chances of satisfactory results are 9007., if used regularly over a period of two to three years. Beneficial results reaching 900/0 can be obtained (11, 21, 29) . It is often necessary to give 20 or more injections before the maintenance dose is reached; therefore, some investi· gators have employed "rush" or "cluster" hyposensitization to titrate up to a higher dose more rapidly (17) . Increased dosages are given every 1·2 hours. under close observation (hospitalization). Once lhe first interim maintenance dose is reached, the standard dose is then followed.
Local hyposensitizat ion with direct stimulation of the shock organ has been used since 1951 , initially against bronchial asthma (10, 16, 33) . Numerous studies have described clinical effects but wellcont rolled, double-blind investigatio ns are necessary 10 uncover any potential effects of the treatment.
Following the development of allergen immunotherapy and its adaptation as a form of standard practice. a number of clinical and scienti fic questions were raised about its nature. With the use of appropriate patient populations, doses of antigens and methods of evaluat ion, there exist clear demonstration of efficacy.
It is of considerable importance. in both clinical pract ice a nd trials, that the allergen immunotherapy results in a reduction but not elimination of symptoms. With the evaluation of allergen immunotherapy, studies on the mechanism of action are conducted by clinical investigators. It was later recognized that the term desensitization was not appropriate, because even after continued therapy and apparent clinical improvement the patients remained reactive 10 allergens. The latter was also demonstrated by the cont inued presence of some symptoms a nd immediate type skin reactivity which led investigators to use the term hyposensitization therapy instead of desensitization therapy and more recently the broader and less mechanistic term allergen immunotherapy (22) .
The clinical improvement follow ing hyposensitization therapy has also been shown to be dose related and should be tailored to the need of the patient.
In order to fulfill the needs of an appropriate therapy it is extremely important to obtain a progress repon of the symptoms befor writing the treatment eXtract. T he objective evaluation of efficacy in the therapy has been the response to bronchial provocalion tests in clinical observat ion ( I, 3) .
Immunologic eHicacy parameters:
Most of the scienti fic knowledge on the mechanism of action of allergen immunotherapy is yet very recent and insufficient. Therefore, it seems appropriate to try to fully understand immunologic mechanisms responsible for the results of immunotherapy and to hope that the principles learned will allow the evaluation o f efficacy by techniques si mpler than full-scale clinical studies. Immunologic studies appear to strive to the goal but fi nal answers have yet to be obtained. As that suppression of IgE antibodies comes about through the stimulation of supressor T --cells (specific for IgE antibodies toward the antigen which the animal has received by parenteral injections). Although hyposensitization is being employed now for 70 years, it has not been possible to clarify the immunological mechanisms or to establish any certain effect parameters (21) . Complete decreased levels of either serum total IgE, serum specific IgE (SS IgE) or both, was not observed during the allergen immunotherapy of extrinsic atopic bronchial asthma (18) . Following the application of a1lergen immunotherapy, serum tota1ly IgO, SSlgG and SS IgO/SS IgE ratio usually increases to relatively higher levels (8) .
Some trials indicated reduced basophilic histamine release (cell sensitivity index) during hyposensi tization (15) . Studies on lymphocyte activity have shown an increase in T-suppressor cells and a post-treatment reduction on lymphoblast transformation (L T), mitogenic factor(MF) and in migration inhibitory factor (MLF) (5, 7). On the other hand, during immunotherapy it has been shown that some serum specific suppressor substances were also particularly detected against IgE (14) . The inhibited histamine-induced suppressor factor (HSF) which is released from T-suppressor cells (previously found as inhibited) gradually increased following the allergen immunotherapy in the atopic individuals (2).
Recent developments in imm un ot herapy:
It has been the goal of many investigators to improve the preparations used in allergen immunotherapy which will aid to reduce the number of injections and increase the therapeutic sa fety. In order to reduce the number of injections slow-release preparations such as oil-emulsions, alum-precipitation and tyrosi ne adsorption ect . have been investigated. Emulsions in oil, resulting in unacceptable local reaction, fail to provide adequate efficacy and dropped from consideration because of potential carcinogenicity Alum-precipitation requiring a course of7 to 10 injections appears to be reasonably efficacious and the inciden, ce of symptoms following the shots is reduced. To prevent the larger local reactions the extract is prepared with pyridine but, questions arise as to the efficacy of treatment when this organic solvent is used (17) .
In L-tyrosine adsorbed depot extracts the release of antigens is slow, but the efficacy was diminished compared to other depot extract (18) . Recent advances in immunotherapy clearly show us that when modi lied allergens are used the allergenicilY is reduced while still retaining effect of immunogenicity. The allergenicity is defined as the ability to elicit an IgE mediated response where the immunogenicity being the ability the induce an IgO antibody response.
If the aUergenicity can be reduced by polymerization of monomeric antigens (due to the concealed antigenic determinants in the polymer) than the amOunt of allergen administered could be increased. In this form, the immunogenicity should be retained because the antigenic determinants are still available for processing by macrophages and initates an IgO antibody response. An equal weight of polymeric antigens would have a lower molecular concentration and decreased opportunity to bridge IgE antibody molecules on mast cells. The selection of allergens included in the treatment extract is based on clinical history and the allergy skin tests (22) . A different way to reduce allergic reactions is to modify the aliergen by various chemical treatments. The allergenicity is then greatly reduced, while maintaining the necessary antigenicity required for the desired immunologic responses. One of the methods used to modify allergen s is a formaldehyde or glutaraldehyde treatment. Formaldehyde-treated materials have been refe rred as allergoids, a term derived rrom allergen as toxoid from toxin. Indeed, allergoid materials do show less allergenic potential by more than hundred folds. The patient can be immunized with fewer doses instead of increased doses given by injection.
Allergoids, appearing to be an improvement over present techniques of immunization , are still under trial and not yet available to the practicing physician. There also exist two modified allergens to mention for parenteral immunization . The first modified material combines extraction with the organic solvent, pyridine, followed by alum·precipitation. The second material is obtained by the treatment of allergens with glutaraldehyde; rollowed by adsorption to suspensions of L-thyrosine (18).
T he future of Immunotherapy: Immunologic comparisons with sta ndard allergenic extract are not available currently and the method requires further evaluation. Moreover. new area accumulating a great interest in terms of immunologi': management of allergies is to be mentioned despite its unknown practical value.
Urea-denaturated materials are non-antigenic and stimulate little or no IgO antibody response but produce suppression of 'gE synthesis. To date, to degree of suppression of IgE synt hesis has been too small to be clinically useful. but deserves further investigations.
Other methods of inducing T cell suppression have also been tried. Polyethylene glycol-substituted aUergens have been offered as a way of either producing stimulation of suppressor T·cell or inducing some other suppression mechanisms of IgE synthesis. It is also possible to induce a B cell tolerance in animals by adding short chained const ituents to antigens (principally a copolymer of D-Glutamic acid and D-Iysine) .
It has been suggested that suppression of antibody responses can be induced by the administration of allergen-antibody conjugate a nd experiments in animals have been producing interesti ng results in th is direct ion (18) .
Conclusion:
Cont rolled observations have confirmed many, but not all , of the em pirical observations on the clinical effec ts of immunization wit h a llergenic extracts. T hese immunologic methods provide valuable but yet imcomplete clues for the mechanisms of im munization. Such observations do however, provide clues for better ways of immunizing patients. Shorter courses of immunization with less side erfects do also appear to be possible in the near fUlure, We hope to see reliable improvemenu in immunotherapy that will furth er shorten the course o f immunization, eliminate allergic side effects and improve effi cacy in the years ahead .
